Inside the KLOW blend: the four components, and how far the literature on each one goes

The KLOW blend is four compounds co-lyophilised in a single vial. That is a convenience and a constraint at the same time, and most writing about it covers only the convenience.

What is in the vial:

A 5:1:1:1 ratio by mass, GHK-Cu dominant. That composition is a statement about what is in the vial, not an instruction about anything.

The useful question is not whether four mechanisms sound complementary. It is what the literature on each compound examined, how far each one got, and what happens to all of it in one container.

GHK-Cu — the most-studied component, and the one with the most invested reviewer

GHK-Cu is a copper-bound tripeptide and the oldest thread here. Loren Pickart identified GHK in the 1970s, and the body of work on it is larger than for the other three combined. Pickart and Margolina's review is the usual entry point (PMID 29986520), surveying the gene-expression work — GHK-Cu altering expression across a large number of genes in cultured human fibroblasts, collagen genes among them — alongside collagen synthesis in culture and animal wound models.

Two things to hold alongside it. The review is by the compound's discoverer, who has a long commercial association with it — not disqualifying, but not independent assessment either. And the copper is not incidental: copper-dependent enzymes are part of the proposed mechanism, so GHK-Cu and GHK are not interchangeable in the way the names suggest.

Evidence stage: cell culture and animal models, with cosmetic-grade human skin work. Not an approved drug.

For more on the copper chemistry, see Copper Peptides Explained and GHK-Cu for Wound Healing Research.

BPC-157 — angiogenesis, one laboratory, no identified receptor

BPC-157 is a fifteen–amino acid sequence derived from a protein in human gastric juice. The literature runs through angiogenesis — new blood vessel formation — with work pointing at VEGF receptor signalling and the nitric oxide pathway. Sikiric and colleagues' review covers the gastrointestinal origins of that programme (PMID 21548867).

The weaknesses are specific. Almost the entire literature traces to one group at the University of Zagreb, so most findings share a set of methods and assumptions and independent replication is thin. No receptor has been identified, which makes the compound hard to study systematically. And BPC-157 is on the World Anti-Doping Agency's prohibited list, which matters to anyone who competes.

Evidence stage: rodent models with supporting cell culture. An early-phase clinical programme under the code PL 14736 examined inflammatory bowel disease and did not reach approval.

See What Is BPC-157? and BPC-157 for Brain-Gut Axis Research.

TB-500 — a fragment of the thing the papers are about

This is the gap most descriptions skip. Nearly all of the published work is on full-length thymosin beta-4, a 43–44 residue actin-sequestering protein; Goldstein, Hannappel and Kleinman's review is the standard account of how that protein came to be studied in tissue repair (PMID 16099219). TB-500 is a short fragment of it.

The fragment was chosen because it carries the actin-binding region, and the reasoning is sound. But a fragment is not the protein, and a paper on full-length Tβ4 is evidence about full-length Tβ4 — so check which molecule each study used. Full-length Tβ4 has been through early clinical trials; none produced an approval.

The mechanism the work concerns is cell migration — fibroblasts, endothelial cells and immune cells physically reaching a site before they can do anything there. See TB-500 for Tendon and Ligament Research and TB-500 for Cardiac Research.

Evidence stage: cell culture and animal models, with a clinical history belonging to the full-length protein rather than the fragment.

KPV — three amino acids, and the component that makes KLOW not GLOW

KPV is Lys-Pro-Val, the C-terminal tripeptide of α-MSH. It is the 'K' in KLOW and the only component GLOW does not contain.

The cleanest paper in this set is Dalmasso and colleagues, who examined KPV uptake through the PepT1 transporter and reported reduced intestinal inflammation in mouse colitis models and in cell culture (PMID 18061177). A named transporter, a named model, a reported effect on inflammatory markers.

What it is not is a result about skin, or about the other three compounds, or about a person. The α-MSH connection makes KPV interesting for skin research in principle — see KPV for Skin Research — but the strongest published work is intestinal, and the IBD thread is where to read it.

Evidence stage: cell culture and mouse models. Not an approved drug.

Four compounds is four sets of unknowns, not four sets of evidence

This is the part that matters most, and it cuts against the formulation.

There is no published study of this four-component combination. Not of the mixture, not of the 5:1:1:1 ratio, not of the four together in any model. The four-mechanism account above is a rationale assembled from four separate literatures, not evidence about KLOW.

Combining unapproved compounds multiplies the unknowns. Each of the four is unapproved by Health Canada, the FDA and the EMA. Four of them in one vial is not better evidenced than any one of them alone — it is four unknown safety profiles, an unknown interaction profile, and no interaction data of any kind. A blend of four unapproved compounds is less characterised than its parts, not more.

It is attributionally opaque. If something is observed in a model given the mixture, nothing tells you which component produced it, or whether two of them did between them. Where a question needs a mechanism identified, single compounds are the better instrument.

The ratio is fixed. You cannot vary GHK-Cu without varying the other three, because they share a vial. Reconstitution arithmetic follows the total: dissolving the 80 mg vial in 2 mL of bacteriostatic water gives 40 mg/mL of total peptide, which is 25 mg/mL GHK-Cu and 5 mg/mL of each of the other three. The components stay locked in proportion at every concentration.

Stability is shared. One vial means one storage condition and one shelf life for four different molecules. The single-compound literature says nothing about how the mixture behaves in storage.

Where a blend is genuinely the better buy

Two reasons, both practical rather than biological. A co-formulated vial is one reconstitution and one set of documentation instead of four, with the ratio consistent between vials rather than recreated by hand. And a blend generally costs less than buying its components separately at equivalent quantities — check the product pages for current prices against BPC-157, GHK-Cu, TB-500 and KPV.

What a blend does not buy is a shortcut through the evidence problem. For the three-component comparison, see Inside the GLOW Blend and GLOW vs KLOW; for the general case, When Do You Actually Need a Peptide Blend?. Nothing here is medical, dosing or therapeutic guidance.

KLOW is supplied here as the KLOW Blend 80 mg, with each of the four peptides confirmed separately on the batch. Janoshik-verified by HPLC with mass-spec identity confirmation; 100% synthetic. The measured purity for each lot is stated on its product page. Reconstitute in bacteriostatic water. For laboratory research use only.

Common questions

Has the four-component combination itself been studied? No. There is no published trial or animal study of this mixture. Everything written about it, here included, is assembled from the literature on the four compounds separately — which is a weaker thing than it looks.

Is a four-component blend better evidenced than a single compound? The opposite. Each compound carries its own unknowns, and combining them adds an interaction profile nobody has characterised. More compounds in a vial means less is known about what is in it.

Why is the GHK-Cu component five times the others by mass? The published GHK-Cu work has generally used larger quantities than the work on the other three, and the ratio reflects that convention. It is a convention, not a determined optimum — no study has compared ratios of this mixture.

Is any of this approved in Canada? No. None of the four compounds is an approved drug in Canada, by Health Canada or anyone else, and the blend is sold as research material for laboratory use only. It is not sold for human use.

Selected Research References

1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide. International Journal of Molecular Sciences. 2018;19(7):1987. pubmed.ncbi.nlm.nih.gov/29986520
2. Sikiric P, Seiwerth S, Rucman R, et al. Stable Gastric Pentadecapeptide BPC 157: Novel Therapy in Gastrointestinal Tract. Current Pharmaceutical Design. 2011;17(16):1612-1632. pubmed.ncbi.nlm.nih.gov/21548867
3. Goldstein AL, Hannappel E, Kleinman HK. Thymosin Beta-4: Actin-Sequestering Protein Moonlights to Repair Injured Tissues. Trends in Molecular Medicine. 2005;11(9):421-429. pubmed.ncbi.nlm.nih.gov/16099219
4. Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-Mediated Tripeptide KPV Uptake Reduces Intestinal Inflammation. Gastroenterology. 2008;134(1):166-178. pubmed.ncbi.nlm.nih.gov/18061177

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.